Pralsetinib Market
The market for Pralsetinib was estimated at $1.1 billion in 2024; it is anticipated to increase to $1.9 billion by 2030, with projections indicating growth to around $2.9 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Pralsetinib Market Outlook
Revenue, 2024
$1.1B
Forecast, 2034
$2.6B
CAGR, 2025 - 2034
9.1%
The Pralsetinib industry revenue is expected to be around $1.2 billion in 2025 and expected to showcase growth with 9.1% CAGR between 2025 and 2034. The market continues to gain strategic importance within the precision oncology and targeted cancer therapeutics landscape, supported by the increasing adoption of biomarker driven treatment approaches in modern oncology care. Rising prevalence of RET fusion positive cancers, expanding molecular diagnostic testing, and growing awareness regarding personalized cancer therapies are contributing to sustained demand across hospitals and specialty oncology centers. Healthcare providers are increasingly prioritizing selective targeted therapies that improve treatment outcomes while supporting precision medicine initiatives. In addition, advancements in genomic profiling technologies, increasing oncology research investments, and expanding access to companion diagnostics are reinforcing the ongoing clinical and commercial relevance of Pralsetinib across global cancer treatment markets.
Pralsetinib is a targeted kinase inhibitor primarily used for the treatment of RET fusion positive non small cell lung cancer and certain thyroid cancers. The drug selectively inhibits RET altered signaling pathways, helping slow tumor progression and improve disease management in patients with specific genetic mutations. It is commonly administered as an oral therapy in oncology hospitals, cancer specialty clinics, and precision medicine treatment programs. Recent market trends indicate rising demand for targeted oncology drugs driven by increasing genomic testing adoption and growing preference for personalized cancer care strategies. Pharmaceutical companies are expanding collaborations with diagnostic firms to improve identification of RET positive patient populations and strengthen precision oncology treatment pathways. Additionally, increasing regulatory approvals for targeted cancer therapies, expanding clinical research in rare oncogenic mutations, and growing investments in molecular oncology infrastructure are supporting long term demand for Pralsetinib across developed and emerging oncology healthcare ecosystems.
Market Key Insights
The Pralsetinib market is projected to grow from $1.1 billion in 2024 to $2.6 billion in 2034. This represents a CAGR of 9.1%, reflecting rising demand across Lung Cancer Treatment, High-Grade Neuroendocrine Cancer Treatment, and Advanced Thyroid Cancer Treatment.
Blueprint Medicines, Genentech Inc, Roche Holding AG are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Pralsetinib market and are expected to observe the growth CAGR of 6.6% to 9.6% between 2024 and 2030.
Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.7% to 11.4%.
Transition like Transition From Conventional Chemotherapy Toward Precision Targeted Oncology Treatment Models is expected to add $190 million to the Pralsetinib market growth by 2030.
The Pralsetinib market is set to add $1.5 billion between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.
With Increase in ret-altered cancers, and emerging Personalized Medicine, Pralsetinib market to expand 139% between 2024 and 2034.
Opportunities in the Pralsetinib
The rapid expansion of molecular diagnostic testing across Asia Pacific oncology centers is also creating significant opportunities for Pralsetinib in RET fusion positive lung cancer treatment. Countries such as China, Japan, and South Korea are increasing investments in precision oncology infrastructure and genomic sequencing technologies to improve early mutation identification. Oncology hospitals and specialized cancer diagnostic laboratories are expected to become the fastest growing end users due to rising demand for biomarker driven treatment strategies. Oral Pralsetinib formulations are witnessing increasing adoption as healthcare providers prioritize targeted therapies with improved clinical outcomes for advanced non small cell lung cancer patients.
Growth Opportunities in North America and Europe
Being a major hub for pharmaceutical innovation, North America presents a significant market potential for Pralsetinib. This is driven by an ever-increasing patient pool for non-small cell lung cancer and thyroid cancer, two critical application region's for Pralsetinib. Furthermore, the region showcases high competition levels due to the presence of top pharma giants focused on cancer therapeutics. However, the vast potential and heightened competition also unlock opportunities for collaborations, mergers, and acquisitions, helping companies improve their drug portfolios and maximizing patient outreach. Another critical driver for Pralsetinibs market in this region is the increasing support for research and development around targeted therapies.
Parallel to North America, Europe carries significant market potential for Pralsetinib. With advanced healthcare systems across much of the region, There is notable demand for cutting-edge cancer therapeutics, thus providing high-growth opportunities. The competition also remains high here, chiefly from companies that specialize in oncology, thus invigorating the market further. The primary market driver here is Europe's changing demographics, with an aging population that increasingly requires therapeutic interventions in cancer. Finally, making a strong case for Pralsetinib in Europe are the large-scale initiatives to fund research and development activities in oncology, further bolstering its adoption potential.
Market Dynamics and Supply Chain
01
Driver: Expanding Precision Oncology Adoption And Rising RET Fusion Cancer Diagnosis Rates
The growing adoption of precision oncology and increasing diagnosis of RET fusion positive cancers are also major drivers supporting the Pralsetinib market. Healthcare providers are also increasingly integrating genomic profiling and biomarker testing into routine oncology care to identify patients eligible for targeted therapies. This trend is also significantly improving detection rates of RET altered non small cell lung cancer and thyroid cancer, expanding the potential treatment population for Pralsetinib. Simultaneously, advancements in next generation sequencing technologies and companion diagnostics are also enhancing the accuracy and accessibility of molecular testing across oncology centers globally. Pharmaceutical companies and diagnostic firms are also also forming strategic collaborations to strengthen personalized treatment pathways. In addition, rising investments in precision medicine infrastructure and growing awareness regarding mutation specific cancer therapies are also accelerating demand for targeted oncology drugs such as Pralsetinib across developed and emerging healthcare markets.
Rising investments in oncology research focused on rare oncogenic mutations are also significantly driving the growth of the Pralsetinib market. Pharmaceutical companies, biotechnology firms, and cancer research institutes are also increasingly prioritizing targeted therapies designed for genetically defined patient populations. This trend is also expanding clinical trial activity involving RET driven cancers and supporting broader development of precision oncology treatment protocols. Regulatory agencies are also also providing accelerated approval pathways for innovative therapies targeting rare cancer mutations, improving market accessibility. Additionally, growing collaboration between academic cancer centers and biopharmaceutical companies is also strengthening research into advanced targeted treatment combinations. These developments are also enhancing physician confidence in molecularly targeted therapies and supporting long term demand for Pralsetinib across specialized oncology care settings globally.
02
Restraint: Limited Eligible Patient Population Restricting Broad Commercial Oncology Market Expansion Globally
A major restraint affecting the Pralsetinib market is the relatively limited patient population eligible for RET targeted therapies. The drug is specifically prescribed for cancers with RET fusion or RET mutation biomarkers, which represent a small percentage of overall lung and thyroid cancer cases. This narrow treatment population restricts prescription volumes and limits large scale commercial expansion opportunities compared to broader oncology therapies. For example, many oncology centers must conduct specialized genomic testing before identifying suitable candidates, reducing immediate treatment adoption. As a result, pharmaceutical companies face challenges in achieving wider market penetration and sustaining high revenue growth across competitive precision oncology markets.
03
Opportunity: Growing Precision Thyroid Cancer Programs Among European Specialty Oncology Institutions Rapidly and Increasing Rare Cancer Clinical Trials Supporting Targeted Oncology Drug Development Globally
Increasing development of precision thyroid cancer programs across Europe is generating strong growth opportunities for Pralsetinib within endocrine oncology applications. Countries including Germany, France, and the United Kingdom are strengthening molecular oncology initiatives focused on RET altered thyroid cancer management. Specialty oncology clinics and academic cancer research centers are increasingly integrating genomic profiling into advanced thyroid cancer treatment protocols. Pralsetinib oral targeted therapy is expected to witness substantial demand growth due to its effectiveness in mutation specific disease management. Additionally, expanding collaborations between pharmaceutical companies and European cancer institutes are supporting clinical research and improving access to targeted oncology treatments across the region.
The growing number of clinical trials focused on rare oncogenic mutations is creating new opportunities for Pralsetinib across specialized oncology markets worldwide. Pharmaceutical companies and biotechnology firms are increasingly investing in targeted therapies for genetically defined cancers with limited treatment options. Research institutions and cancer specialty hospitals are expanding studies involving RET driven neuroendocrine tumors and advanced solid malignancies. This trend is expected to accelerate demand for Pralsetinib within precision medicine focused oncology applications. Additionally, advances in next generation sequencing technologies and companion diagnostic partnerships are improving patient identification rates, supporting broader adoption of targeted cancer therapies across global oncology healthcare systems.
04
Challenge: High Treatment Costs And Reimbursement Challenges Limiting Accessibility Across Emerging Healthcare Systems
The high cost associated with targeted oncology therapies is significantly restraining demand for Pralsetinib, particularly in price sensitive healthcare markets. Precision cancer treatments often require advanced molecular diagnostics, long term therapy management, and specialty oncology care, increasing the overall financial burden on healthcare systems and patients. In many developing regions, limited reimbursement coverage and restricted insurance support reduce patient access to high value targeted therapies. For instance, hospitals in lower income healthcare systems may prioritize lower cost chemotherapy options over expensive biomarker driven treatments. This affordability challenge slows treatment adoption, reduces market accessibility, and intensifies pricing pressure within the global targeted oncology therapeutics industry.
Supply Chain Landscape
1
Raw Material Procurement
CarbosynthRgenta Therapeutics
2
API Synthesis
WuXi AppTecJohnson Matthey
3
Drug Formulation
Blueprint MedicinesKeyTec
4
Retail & Distribution
Celgene CorporationNovartis
1
Raw Material Procurement
CarbosynthRgenta Therapeutics
2
API Synthesis
WuXi AppTecJohnson Matthey
3
Drug Formulation
Blueprint MedicinesKeyTec
4
Retail & Distribution
Celgene CorporationNovartis
Use Cases of Pralsetinib in Lung Cancer Treatment & High-Grade Neuroendocrine Cancer Treatment
Lung Cancer Treatment : Pralsetinib is extensively used in lung cancer treatment, particularly for patients with RET fusion positive non small cell lung cancer. Oral capsule formulations are primarily prescribed in oncology hospitals, cancer specialty clinics, and precision medicine treatment centers where genomic profiling is routinely conducted. The therapy works by selectively inhibiting RET driven tumor signaling pathways, helping reduce tumor progression and improve progression free survival outcomes. Its targeted mechanism provides significant advantages compared to conventional chemotherapy by offering more personalized treatment with improved tolerability for eligible patients. Increasing adoption of molecular diagnostic testing and rising prevalence of genetically driven lung cancers are significantly supporting demand for Pralsetinib across advanced oncology treatment programs globally.
High-Grade Neuroendocrine Cancer Treatment : Pralsetinib is increasingly being explored for high grade neuroendocrine cancer treatment in patients with RET altered tumor profiles. Specialty oncology centers and research focused cancer institutes are the primary end users utilizing oral targeted therapy formulations for advanced and difficult to treat neuroendocrine malignancies. The drug offers a precision oncology approach by targeting specific oncogenic mutations that contribute to aggressive tumor growth and metastasis. Its selective inhibition capabilities provide opportunities for improved disease control in patients who may not respond effectively to standard chemotherapy regimens. Growing investments in rare cancer research, expansion of genomic sequencing technologies, and increasing clinical trial activity are contributing to broader interest in Pralsetinib within neuroendocrine oncology applications worldwide.
Advanced Thyroid Cancer Treatment : Pralsetinib plays a significant role in the treatment of advanced thyroid cancers, particularly RET fusion positive and RET mutated thyroid malignancies. Oral targeted therapy capsules are widely prescribed in endocrine oncology departments and specialized cancer treatment centers for patients with metastatic or treatment resistant thyroid cancer conditions. The therapy helps inhibit abnormal RET signaling activity responsible for tumor development and progression, supporting improved clinical outcomes and disease management. Its precision medicine approach provides advantages by enabling mutation specific treatment strategies that reduce reliance on broad spectrum systemic therapies. Rising incidence of thyroid cancer, increasing use of molecular diagnostics, and expanding precision oncology programs are driving sustained demand for Pralsetinib in advanced thyroid cancer treatment markets globally.
Impact of Industry Transitions on the Pralsetinib Market
As a core segment of the Pharmaceutical industry,
the Pralsetinib market develops in line with broader industry shifts.
Over recent years, transitions such as Transition From Conventional Chemotherapy Toward Precision Targeted Oncology Treatment Models and Transition From General Oncology Care Toward Biomarker Driven Cancer Management Ecosystems have redefined priorities
across the Pharmaceutical sector,
influencing how the Pralsetinib market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition From Conventional Chemotherapy Toward Precision Targeted Oncology Treatment Models
The Pralsetinib market is contributing to a major transition from traditional chemotherapy based cancer treatment toward precision targeted oncology approaches. Healthcare providers are increasingly using genomic profiling and biomarker testing to identify RET fusion positive cancer patients eligible for personalized therapies. This transition is significantly impacting oncology hospitals, molecular diagnostic companies, and cancer research institutions that are expanding precision medicine capabilities. For example, specialty oncology centers are integrating next generation sequencing technologies into routine cancer diagnostics to support targeted therapy selection. The shift is also encouraging pharmaceutical companies to invest in mutation specific drug development and companion diagnostic partnerships, accelerating innovation across the global oncology therapeutics industry.
02
Transition From General Oncology Care Toward Biomarker Driven Cancer Management Ecosystems
Growing adoption of Pralsetinib is supporting the transition from generalized oncology treatment protocols toward biomarker driven cancer management ecosystems. Oncologists are increasingly prioritizing molecularly targeted therapies for patients with rare oncogenic mutations to improve treatment personalization and clinical outcomes. This trend is influencing diagnostic laboratories, teleoncology platforms, and specialty cancer clinics that are strengthening genomic testing and targeted treatment infrastructure. For instance, cancer centers are expanding precision oncology programs focused on RET altered lung and thyroid cancers. The transition is also driving collaboration between biotechnology firms and diagnostic providers to improve patient identification, streamline treatment pathways, and strengthen personalized cancer care delivery worldwide.